BridgeMD
New treatment option for Cognitive Disorder
Official title A Mixed Intervention to Improve Resilience for Patient With Neurocognitive Disorders
ClinicalTrials.gov ID: NCT06801171
What this study is testing
- What it's testing
- The study aims to test a program combining cognitive behavioral therapy techniques, positive psychology techniques, mindfulness meditation and yoga, in order to improve resilience in patient with minor cognitive disorder. This intervention will be compared to a control group, but also with a group testing another intervention (an intervention that does not improve resilience in the elderly, namely a "cognitive stimulation" intervention) in order to ensure that the effect potentially obtained is not due to the simple management of the participant.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 60 and older
You may be able to join if
- Man or Woman aged \> 60 years
- Have a minor neurocognitive disorder according to the criteria of the DSM 5
- Score of 145 or less on the Wagnild and Young Resilience Scale (RS) (Wagnild, 2009).
- Subject able to read and write French;
- Subject beneficiaries of a social security scheme;
You likely can't join if
- Subject already practicing meditation and/or yoga and/or Tai Chi
- Subject currently undergoing psychological therapy (whatever the approach)
- Subject with a major hearing, visual or motor disability likely to interfere with the proposed interventions or the performance of assessments;
- Presence and/or recent history (within the last 5 years prior to inclusion in the study) of major psychiatric disorders (e.g., schizophrenia, severe...
- If taking psychotropic treatment, the dose must have been stable for 4 weeks
- Vulnerable persons are defined in Articles L1121-5 to -8
See the full eligibility criteria
- Man or Woman aged \> 60 years
- Have a minor neurocognitive disorder according to the criteria of the DSM 5
- Score of 145 or less on the Wagnild and Young Resilience Scale (RS) (Wagnild, 2009).
- Subject able to read and write French;
- Subject beneficiaries of a social security scheme;
- Ability to understand and sign free and informed consent.
- Subject already practicing meditation and/or yoga and/or Tai Chi
- Subject currently undergoing psychological therapy (whatever the approach)
- Subject with a major hearing, visual or motor disability likely to interfere with the proposed interventions or the performance of assessments;
- Presence and/or recent history (within the last 5 years prior to inclusion in the study) of major psychiatric disorders (e.g., schizophrenia, severe depression, addiction, bipolar disorders, psychotic disorders, risk of...
- If taking psychotropic treatment, the dose must have been stable for 4 weeks
- Vulnerable persons are defined in Articles L1121-5 to -8
The study team makes the final eligibility decision.
Where it's taking place
- Nice, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 60 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nice, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.